Charles River Laboratories International Beheer
Beheer criteriumcontroles 3/4
Charles River Laboratories International's CEO is Jim Foster, appointed in Jan 1991, has a tenure of 33.83 years. total yearly compensation is $14.10M, comprised of 10.4% salary and 89.6% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth $42.77M. The average tenure of the management team and the board of directors is 5 years and 7.3 years respectively.
Belangrijke informatie
Jim Foster
Algemeen directeur
US$14.1m
Totale compensatie
| Percentage CEO-salaris | 10.4% |
| Dienstverband CEO | 33.8yrs |
| Eigendom CEO | 0.5% |
| Management gemiddelde ambtstermijn | 5yrs |
| Gemiddelde ambtstermijn bestuur | 7.3yrs |
Recente managementupdates
Recent updates
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Oct 11Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 29 2024 | n/a | n/a | US$432m |
| Mar 30 2024 | n/a | n/a | US$439m |
| Dec 30 2023 | n/a | n/a | US$475m |
| Sep 30 2023 | n/a | n/a | US$475m |
| Jul 01 2023 | n/a | n/a | US$484m |
| Apr 01 2023 | n/a | n/a | US$496m |
| Dec 31 2022 | US$13m | US$1m | US$486m |
| Sep 24 2022 | n/a | n/a | US$436m |
| Jun 25 2022 | n/a | n/a | US$443m |
| Mar 26 2022 | n/a | n/a | US$422m |
| Dec 25 2021 | US$14m | US$1m | US$391m |
| Sep 25 2021 | n/a | n/a | US$397m |
| Jun 26 2021 | n/a | n/a | US$396m |
| Mar 27 2021 | n/a | n/a | US$375m |
| Dec 26 2020 | US$13m | US$1m | US$364m |
| Sep 26 2020 | n/a | n/a | US$301m |
| Jun 27 2020 | n/a | n/a | US$271m |
| Mar 28 2020 | n/a | n/a | US$248m |
| Dec 28 2019 | US$18m | US$1m | US$252m |
| Sep 28 2019 | n/a | n/a | US$231m |
| Jun 29 2019 | n/a | n/a | US$219m |
| Mar 30 2019 | n/a | n/a | US$227m |
| Dec 29 2018 | US$14m | US$1m | US$225m |
| Sep 29 2018 | n/a | n/a | US$135m |
| Jun 30 2018 | n/a | n/a | US$128m |
| Mar 31 2018 | n/a | n/a | US$129m |
| Dec 30 2017 | US$13m | US$1m | US$123m |
Compensatie versus markt: Jim's total compensation ($USD14.10M) is above average for companies of similar size in the US market ($USD8.06M).
Compensatie versus inkomsten: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Foster (73 yo)
33.8yrs
Tenure
US$14,096,923
Compensatie
Mr. James C. Foster, J.D. has been the Chairman of the Board at Charles River Laboratories, Inc. (CRL) since 2000 and has been its Chief Executive Officer since 1992 and serves as its President since 1991....
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Chairman | 33.8yrs | US$14.10m | 0.46% $ 42.8m | |
| Corporate Executive VP & CFO | 2.5yrs | US$3.81m | 0.0049% $ 456.9k | |
| Corporate Executive VP & COO | 3yrs | US$4.99m | 0.082% $ 7.7m | |
| Corporate Executive Vice President of Corporate Development & Strategy | 13.8yrs | US$3.06m | 0.021% $ 2.0m | |
| Corporate Executive Vice President of Community Relations | 8.1yrs | US$2.91m | 0.051% $ 4.8m | |
| Corporate Senior VP & Chief Accounting Officer | 7.6yrs | geen gegevens | 0.010% $ 962.3k | |
| Corporate Senior VP & Chief Scientific Officer | 3yrs | geen gegevens | geen gegevens | |
| Corporate Senior VP & Chief Information Officer | 3.4yrs | geen gegevens | geen gegevens | |
| Corporate Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Corporate Senior VP | 4.2yrs | geen gegevens | geen gegevens | |
| Corporate Vice President & Chief Communications Officer | no data | geen gegevens | geen gegevens | |
| Corporate Executive VP & Chief People Officer | 5.8yrs | geen gegevens | 0.020% $ 1.9m |
5.0yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: CRL's management team is seasoned and experienced (5 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Chairman | 35.8yrs | US$14.10m | 0.46% $ 42.8m | |
| Independent Director | 13.8yrs | US$339.77k | 0.046% $ 4.3m | |
| Lead Independent Director | 21.8yrs | US$371.02k | 0.010% $ 958.6k | |
| Independent Director | 5.1yrs | US$346.02k | 0.0066% $ 616.6k | |
| Independent Director | 13.8yrs | US$346.02k | 0.062% $ 5.8m | |
| Independent Director | 1.9yrs | US$437.78k | 0.0018% $ 164.4k | |
| Director | 7.3yrs | US$336.02k | 0.022% $ 2.1m | |
| Independent Director | 16.1yrs | US$339.77k | 0.014% $ 1.3m | |
| Independent Director | 4.8yrs | US$339.77k | 0.0048% $ 444.7k | |
| Independent Director | 4.1yrs | US$324.77k | 0.0048% $ 449.4k | |
| Independent Director | less than a year | geen gegevens | 0.00033% $ 30.8k |
7.3yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: CRL's board of directors are considered experienced (7.3 years average tenure).